Our study sought approaches for chronic liver failure (CLF) treatment and correction via cell-engineered constructs (CECs). They are built from biopolymer-based, microstructured, and collagen-containing hydrogel (BMCG). We also strove to evaluate the functional activity of BMCG in liver regeneration. Materials and Methods: Allogeneic liver cells (namely, hepatocytes; LC) together with mesenchymal multipotent stem cells of bone marrow origin (MMSC BM; BMSCs) were adhered to our BMCG to compose implanted liver CECs. Thereafter, we investigated a model of CLF in rats receiving the implanted CECs. The CLF had been provoked by long-term exposure to carbon tetrachloride. The study comprised male Wistar rats (n = 120) randomized into 3 groups: Group 1 was a control group with the saline treatment of the hepatic parenchyma (n = 40); Group 2 received BMCG only (n = 40); and Group 3 was loaded with CECs implanted into the parenchyma of their livers (n = 40). August rats (n = 30) made up a donor population for LCs and MMSC BM to develop grafts for animals from Group 3. The study length was 90 days. Results: CECs were shown to affect both biochemical test values and morphological parameters in rats with CLF. Conclusion: We found BMCG-derived CECs to be operational and active, with regenerative potential. Group 3 showed significant evidence of forced liver regeneration that tended to persist until the end of the study (day 90). The phenomenon is reflected by biochemical signs of hepatic functional recovery by day 30 after grafting (compared to Groups 1 and 2), whereas structural features of liver repair (necrosis prevention, missing formation of vacuoles, degenerating LC number decrease, and delay of hepatic fibrotic transformation). Such implantation of BMCG-derived CECs with allogeneic LCs and MMSC BM might represent a proper option to correct and treat CLF, as well as to maintain affected liver function in patients with liver grafting needed.
Aim: In this study, we seek to check if recombinant spidroin rS1/9 is applicable for cell-engineering construct development. Novel technologies of cell and tissue engineering are relevant for chronic liver failure management. Liver regeneration may represent one of the possible treatment options if a cell-engineered construct (CEC) is used. Nowadays, one can see the continuous study of various matrices to create an appropriate CEC. Materials and Methods: We have adhered allogenic liver cells and multipotent mesenchymal bone marrow stem cells (MMSC BM) to a microgel with recombinant spidroin rS1/9. Then we have studied the developed implantable CEC in a rat model (n = 80) of chronic liver failure achieved by prolonged poisoning with carbon tetrachloride. Results: Our results demonstrate that the CECs change the values of biochemical tests and morphological parameters in chronic liver failure in rats. Conclusion: We consider there to be a positive effect from the microgel-based CECs with recombinant spidroin rS1/9 in the treatment of chronic liver failure.
Producing a tissue-engineered pancreas based on a tissue-specific scaffold from a decellularized pancreas, imitating the natural pancreatic tissue microenvironment and the islets of Langerhans, is one of the approaches to treating patients with type 1 diabetes mellitus (T1DM). The aim of this work was to investigate the ability of a fine-dispersed tissue-specific scaffold (DP scaffold) from decellularized human pancreas fragments to support the islets’ survival and insulin-producing function when injected in a streptozotocin-induced diabetic rat model. The developed decellularization protocol allows us to obtain a scaffold with a low DNA content (33 [26; 38] ng/mg of tissue, p < 0.05) and with the preservation of GAGs (0.92 [0.84; 1.16] µg/mg, p < 0.05) and fibrillar collagen (273.7 [241.2; 303.0] µg/mg, p < 0.05). Rat islets of Langerhans were seeded in the obtained scaffolds. The rats with stable T1DM were treated by intraperitoneal injections of rat islets alone and islets seeded on the DP scaffold. The blood glucose level was determined for 10 weeks with a histological examination of experimental animals’ pancreas. A more pronounced decrease in the recipient rats’ glycemia was detected after comparing the islets seeded on the DP scaffold with the control injection (by 71.4% and 51.2%, respectively). It has been shown that the DP scaffold facilitates a longer survival and the efficient function of pancreatic islets in vivo and can be used to engineer a pancreas.
Hematopoietic stem cells derived from bone marrow are known to induce tissue repair. Their mechanisms to induce liver regeneration are not clear and may have numerous adverse effects. We compared the regenerative potential of intact hematopoietic stem cells (iHSCs), their total RNA, and apoptotic hematopoietic stem cells (aHSCs) in liver damage. Male Wistar rats (n = 40 per group) experienced a 75% liver resection and received single intraperitoneal injections of saline (control group), iHSCs, aHSCs, or total RNA of iHSCs. We recorded animal survival, liver mass, blood markers of liver cell lysis and function (albumin, aminotransferases, alkaline phosphatase), and liver histological features: mitotic index and expression of markers for proliferation and apoptosis (caspase-9, caspase-3, and Ki-67). We assessed the survival with the log-rank test and used Wilcoxon and t tests for the other parameters. Animals of all HSC- or RNA-treated groups survived until the end of the experiment with full blood marker recovery (p = 0.037). The liver mass enlarged mostly after apoptotic hematopoietic stem cells and total RNA. Mitotic index peaked in the group of total RNA with a lower but earlier increase for the aHSC group, and Ki-67 proliferation for the total RNA group was the highest (all the differences were significant with p values ˂ 0.05). We found the aHSCs and total RNA of iHSC group to be the most efficient for liver reparation. Total RNA from HSCs is preferred for further liver regeneration studies.
Mesenchymal stem cells (MSCs) are known to assist liver regeneration. In this study, we show a dose-dependent mode of recovery from liver fibrosis after intravenous injections of MSCs. Male Wistar rats experienced a 42-day-long modeling of liver fibrosis via CCl4 poisoning and received either a single injection of 2.5 × 106 MSCs on Day 3 after the last CCl4 dose or two MSC injections on Days 3 and 10. We dynamically monitored levels of liver cytolysis markers and cytokines in the venous blood and performed a histological study of Mallory-stained liver sections. All experimental groups experienced a nearly complete recovery of biochemical markers up to 4 weeks after the end of CCl4 administration, although we observed anti-inflammatory changes in the cytokine levels only in animals treated by two MSC injections. Histological study revealed minor signs of liver damage up to Day 90 in animals receiving two MSC doses with worse pathology in those who received a single MSC dose. Morphometric values stayed consistent with visual data, demonstrating a significantly larger number of binuclear hepatocytes, a smaller number of false lobules, and a lesser area of connective tissue proper in animals treated by two MSC injections. Our results reflect MSC grafting in applied doses to affect liver fibrosis in a dose-dependent mode. These findings provide a deeper understanding of MSC action in liver fibrosis, and the doses applied may serve as a milestone for further studies in humans.
Bioabsorbable scaffolds from synthetic polyesters are widely used in the field of tissue engineering. However, their hydrophobic surface and lack of suitable functional groups are the main limitations related to cell attachment. The aim of this research was to modify the surface of polycaprolactone (PCL) scaffolds using a bioactive coating containing heparin bound via albumin spacer and platelet lysate over heparin. Porous scaffolds were produced by electrospinning from 10% PCL (w/w) solution in methylene chloride (25 kV voltage, 100 mm distance between electrodes and 4 mL/h feedrate), which demonstrated 5.5 ± 1.1 MPa Young’s modulus, 2.5 ± 0.4 MPa tensile strength and 321 ± 29% elongation at break. Bioactive coating does not change the structure and mechanical properties of the scaffolds. Treated scaffolds are biocompatible and have no cytotoxic effect in direct contact with cells. Functionalization also promotes the in vitro adhesion and proliferation of human adipose mesenchymal stromal cells. After 7 days of incubation, the PCL scaffold modified with the heparin–platelet lysate complex had a cell density of 185.6 ± 15.7 cells/mm2 compared to 79.5 ± 7.8 cells/mm2 for nontreated control. The intramuscular implantation of scaffolds revealed that immobilization of heparin alone prolongs the acute phase of the inflammatory reaction. However, subsequent treatment with platelet lysate minimizes the inflammatory reaction, slows the rate of implant absorption, and accelerates vascularization. The results obtained show that the developed bioactive coating improves the cellular properties of PCL electrospun scaffolds and can be used to form in vivo tissue-engineered constructs.